Alector (ALEC) Other Non-Current Liabilities (2018 - 2026)
Alector's (ALEC) quarterly Other Non-Current Liabilities came in at $2.0 million in Q2 2026, up 40.17% year-over-year from $1.4 million in Q2 2025, and up 14.35% quarter-over-quarter from $1.8 million in Q1 2026.
Analysis
Alector (ALEC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Other Non-Current Liabilities for 9 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 40.17% year-over-year to $2.0 million in Q2 2026; TTM through Jun 2026 was $2.0 million, a 40.17% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 40.76% from the prior year.
- Other Non-Current Liabilities was $2.0 million for Q2 2026 at Alector, up from $1.8 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.0 million in Q2 2026 and troughed at $158000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities soared 468.35% in 2023 and declined 10.12% in 2024, its largest moves.
- Over 5 years, Other Non-Current Liabilities stood at $759000.0 in 2022, then surged by 80.9% to $1.4 million in 2023, then decreased by 10.12% to $1.2 million in 2024, then soared by 40.76% to $1.7 million in 2025, then climbed by 16.52% to $2.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $2.0 million (Q2 2026), $1.8 million (Q1 2026), and $1.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Mn |
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 898,000.00 |
| Jun 30, 2023 | 898,000.00 |
| Mar 31, 2023 | 898,000.00 |
| Dec 31, 2022 | 759,000.00 |
| Sep 30, 2022 | 233,000.00 |
| Jun 30, 2022 | 233,000.00 |
| Mar 31, 2022 | 158,000.00 |
| Dec 31, 2021 | 158,000.00 |
| Sep 30, 2021 | 158,000.00 |